Postoperative chemoradiation in patients with localized gastric adenocarcinoma: single center experience
5-Fluorouracil (FU)-based chemotherapy (CT) and concurrent 45 Gy radiotherapy (RT) is one of the standard postoperative approaches currently used in gastric carcinoma. The high toxicity rates of this treatment leads to interruption of treatment in the majority of patients. In our study, we investiga...
Gespeichert in:
Veröffentlicht in: | Indian journal of cancer 2011-01, Vol.48 (1), p.24 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 24 |
container_title | Indian journal of cancer |
container_volume | 48 |
creator | Yoney, A Bati, Y Isikli, L Unsal, M |
description | 5-Fluorouracil (FU)-based chemotherapy (CT) and concurrent 45 Gy radiotherapy (RT) is one of the standard postoperative approaches currently used in gastric carcinoma. The high toxicity rates of this treatment leads to interruption of treatment in the majority of patients. In our study, we investigated the rates of toxicity and treatment discontinuation observed during postoperative FU-based chemoradiotherapy (CRT); retrospectively evaluated the effect of CRT and the other prognostic factors on local and distant control and survival.
A total of 160 patients consisting of 97 total and 63 subtotal gastrectomy receiving postoperative CRT, have been studied retrospectively.
Patients who had to discontinue the treatment for a median of 6 (range, 3-13) days experienced toxicity during treatment at a rate of 43%. During the 21 (range, 4-68) months of follow-up local recurrences were observed in 8 (5%) patients and distant recurrences were observed in 41 (25.6%) patients. While the 1-3 year overall survival (OS) rates were 75% and 42%, 13-year disease-free survival (DFS) rates were 63% and 42%, respectively. In the univariate analysis for OS and DFS demonstrated statistical significance for below those 60 years of age, D1-D2 dissection type, negative surgical margin, early treatment beginning, the absence of invasion, and early stage disease. D1D2 dissection type, early treatment beginning, age below 60 years and early stage disease significantly improve OS and DFS in multivariate analysis.
Survival is worse in patients older than 60 years, had late treatment beginning, advanced stage and D0 dissection. |
doi_str_mv | 10.4103/0019-509X.75816 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_853032357</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A249582178</galeid><sourcerecordid>A249582178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-a01a96bbae62af4a69b23ba7a9d56cea6b121aebc2bd2846d544563be2c386903</originalsourceid><addsrcrecordid>eNptkk1v1DAQhi0EokvhzA1FIHHL1p9JzK2q-JIqwQEkbtbEmWxcJfZie0vLr8fLlopKKx_GM37esTTvEPKS0bVkVJxRynStqP6xblXHmkdkxbTuatm28jFZ3b-ekGcpXVHKBZfdU3LCWYlS0RWZvoaUwxYjZHeNlZ1wCREGV9LgK-erbbmhz6n65fJUzcHC7H7jUG0g5ehsBQP6UozW-bDAuyo5v5lLo6LBWOFNaV30Fp-TJyPMCV_cxVPy_cP7bxef6ssvHz9fnF_WVjKRa6AMdNP3gA2HUUKjey56aEEPqrEITc84A-wt7wfeyWZQUqpG9Mit6BpNxSl5fei7jeHnDlM2V2EXffnSdEpQwYVqC_TmAG1gRuP8GHIEu7hkzTmXWnWctV2h6iPUBn2Z1hw8jq6UH_DrI3w5Ay7OHhW8_U8wIcx5SmHe7WefHoJnB9DGkFLE0WyjWyDeGkbNfhHM3mqzt9r8XYSieHU3hl2_4HDP_3Ne_AH9S62b</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>853032357</pqid></control><display><type>article</type><title>Postoperative chemoradiation in patients with localized gastric adenocarcinoma: single center experience</title><source>MEDLINE</source><source>Medknow Open Access Medical Journals</source><source>Bioline International</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Yoney, A ; Bati, Y ; Isikli, L ; Unsal, M</creator><creatorcontrib>Yoney, A ; Bati, Y ; Isikli, L ; Unsal, M</creatorcontrib><description>5-Fluorouracil (FU)-based chemotherapy (CT) and concurrent 45 Gy radiotherapy (RT) is one of the standard postoperative approaches currently used in gastric carcinoma. The high toxicity rates of this treatment leads to interruption of treatment in the majority of patients. In our study, we investigated the rates of toxicity and treatment discontinuation observed during postoperative FU-based chemoradiotherapy (CRT); retrospectively evaluated the effect of CRT and the other prognostic factors on local and distant control and survival.
A total of 160 patients consisting of 97 total and 63 subtotal gastrectomy receiving postoperative CRT, have been studied retrospectively.
Patients who had to discontinue the treatment for a median of 6 (range, 3-13) days experienced toxicity during treatment at a rate of 43%. During the 21 (range, 4-68) months of follow-up local recurrences were observed in 8 (5%) patients and distant recurrences were observed in 41 (25.6%) patients. While the 1-3 year overall survival (OS) rates were 75% and 42%, 13-year disease-free survival (DFS) rates were 63% and 42%, respectively. In the univariate analysis for OS and DFS demonstrated statistical significance for below those 60 years of age, D1-D2 dissection type, negative surgical margin, early treatment beginning, the absence of invasion, and early stage disease. D1D2 dissection type, early treatment beginning, age below 60 years and early stage disease significantly improve OS and DFS in multivariate analysis.
Survival is worse in patients older than 60 years, had late treatment beginning, advanced stage and D0 dissection.</description><identifier>ISSN: 0019-509X</identifier><identifier>EISSN: 1998-4774</identifier><identifier>DOI: 10.4103/0019-509X.75816</identifier><identifier>PMID: 21248450</identifier><language>eng</language><publisher>India: Medknow Publications and Media Pvt. Ltd</publisher><subject>Adenocarcinoma ; Adenocarcinoma - drug therapy ; Adenocarcinoma - radiotherapy ; Adenocarcinoma - therapy ; Adenocarcinoma, Mucinous - drug therapy ; Adenocarcinoma, Mucinous - radiotherapy ; Adenocarcinoma, Mucinous - therapy ; Adult ; Aged ; Antimetabolites, Antineoplastic - therapeutic use ; Cancer ; Carcinoma, Papillary - drug therapy ; Carcinoma, Papillary - radiotherapy ; Carcinoma, Papillary - therapy ; Carcinoma, Signet Ring Cell - drug therapy ; Carcinoma, Signet Ring Cell - radiotherapy ; Carcinoma, Signet Ring Cell - therapy ; Care and treatment ; Chemotherapy ; Combined Modality Therapy ; Dissection ; Female ; Fluorouracil - therapeutic use ; Follow-Up Studies ; Gastrectomy ; Humans ; Male ; Methods ; Middle Aged ; Mortality ; Patient outcomes ; Postoperative care ; Postoperative period ; Retrospective Studies ; Statistical methods ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - radiotherapy ; Stomach Neoplasms - therapy ; Studies ; Survival analysis ; Survival Rate ; Treatment Outcome</subject><ispartof>Indian journal of cancer, 2011-01, Vol.48 (1), p.24</ispartof><rights>COPYRIGHT 2011 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt. Ltd. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21248450$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoney, A</creatorcontrib><creatorcontrib>Bati, Y</creatorcontrib><creatorcontrib>Isikli, L</creatorcontrib><creatorcontrib>Unsal, M</creatorcontrib><title>Postoperative chemoradiation in patients with localized gastric adenocarcinoma: single center experience</title><title>Indian journal of cancer</title><addtitle>Indian J Cancer</addtitle><description>5-Fluorouracil (FU)-based chemotherapy (CT) and concurrent 45 Gy radiotherapy (RT) is one of the standard postoperative approaches currently used in gastric carcinoma. The high toxicity rates of this treatment leads to interruption of treatment in the majority of patients. In our study, we investigated the rates of toxicity and treatment discontinuation observed during postoperative FU-based chemoradiotherapy (CRT); retrospectively evaluated the effect of CRT and the other prognostic factors on local and distant control and survival.
A total of 160 patients consisting of 97 total and 63 subtotal gastrectomy receiving postoperative CRT, have been studied retrospectively.
Patients who had to discontinue the treatment for a median of 6 (range, 3-13) days experienced toxicity during treatment at a rate of 43%. During the 21 (range, 4-68) months of follow-up local recurrences were observed in 8 (5%) patients and distant recurrences were observed in 41 (25.6%) patients. While the 1-3 year overall survival (OS) rates were 75% and 42%, 13-year disease-free survival (DFS) rates were 63% and 42%, respectively. In the univariate analysis for OS and DFS demonstrated statistical significance for below those 60 years of age, D1-D2 dissection type, negative surgical margin, early treatment beginning, the absence of invasion, and early stage disease. D1D2 dissection type, early treatment beginning, age below 60 years and early stage disease significantly improve OS and DFS in multivariate analysis.
Survival is worse in patients older than 60 years, had late treatment beginning, advanced stage and D0 dissection.</description><subject>Adenocarcinoma</subject><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - radiotherapy</subject><subject>Adenocarcinoma - therapy</subject><subject>Adenocarcinoma, Mucinous - drug therapy</subject><subject>Adenocarcinoma, Mucinous - radiotherapy</subject><subject>Adenocarcinoma, Mucinous - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Cancer</subject><subject>Carcinoma, Papillary - drug therapy</subject><subject>Carcinoma, Papillary - radiotherapy</subject><subject>Carcinoma, Papillary - therapy</subject><subject>Carcinoma, Signet Ring Cell - drug therapy</subject><subject>Carcinoma, Signet Ring Cell - radiotherapy</subject><subject>Carcinoma, Signet Ring Cell - therapy</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Dissection</subject><subject>Female</subject><subject>Fluorouracil - therapeutic use</subject><subject>Follow-Up Studies</subject><subject>Gastrectomy</subject><subject>Humans</subject><subject>Male</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Patient outcomes</subject><subject>Postoperative care</subject><subject>Postoperative period</subject><subject>Retrospective Studies</subject><subject>Statistical methods</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - radiotherapy</subject><subject>Stomach Neoplasms - therapy</subject><subject>Studies</subject><subject>Survival analysis</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0019-509X</issn><issn>1998-4774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhi0EokvhzA1FIHHL1p9JzK2q-JIqwQEkbtbEmWxcJfZie0vLr8fLlopKKx_GM37esTTvEPKS0bVkVJxRynStqP6xblXHmkdkxbTuatm28jFZ3b-ekGcpXVHKBZfdU3LCWYlS0RWZvoaUwxYjZHeNlZ1wCREGV9LgK-erbbmhz6n65fJUzcHC7H7jUG0g5ehsBQP6UozW-bDAuyo5v5lLo6LBWOFNaV30Fp-TJyPMCV_cxVPy_cP7bxef6ssvHz9fnF_WVjKRa6AMdNP3gA2HUUKjey56aEEPqrEITc84A-wt7wfeyWZQUqpG9Mit6BpNxSl5fei7jeHnDlM2V2EXffnSdEpQwYVqC_TmAG1gRuP8GHIEu7hkzTmXWnWctV2h6iPUBn2Z1hw8jq6UH_DrI3w5Ay7OHhW8_U8wIcx5SmHe7WefHoJnB9DGkFLE0WyjWyDeGkbNfhHM3mqzt9r8XYSieHU3hl2_4HDP_3Ne_AH9S62b</recordid><startdate>201101</startdate><enddate>201101</enddate><creator>Yoney, A</creator><creator>Bati, Y</creator><creator>Isikli, L</creator><creator>Unsal, M</creator><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201101</creationdate><title>Postoperative chemoradiation in patients with localized gastric adenocarcinoma: single center experience</title><author>Yoney, A ; Bati, Y ; Isikli, L ; Unsal, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-a01a96bbae62af4a69b23ba7a9d56cea6b121aebc2bd2846d544563be2c386903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adenocarcinoma</topic><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - radiotherapy</topic><topic>Adenocarcinoma - therapy</topic><topic>Adenocarcinoma, Mucinous - drug therapy</topic><topic>Adenocarcinoma, Mucinous - radiotherapy</topic><topic>Adenocarcinoma, Mucinous - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Cancer</topic><topic>Carcinoma, Papillary - drug therapy</topic><topic>Carcinoma, Papillary - radiotherapy</topic><topic>Carcinoma, Papillary - therapy</topic><topic>Carcinoma, Signet Ring Cell - drug therapy</topic><topic>Carcinoma, Signet Ring Cell - radiotherapy</topic><topic>Carcinoma, Signet Ring Cell - therapy</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Dissection</topic><topic>Female</topic><topic>Fluorouracil - therapeutic use</topic><topic>Follow-Up Studies</topic><topic>Gastrectomy</topic><topic>Humans</topic><topic>Male</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Patient outcomes</topic><topic>Postoperative care</topic><topic>Postoperative period</topic><topic>Retrospective Studies</topic><topic>Statistical methods</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - radiotherapy</topic><topic>Stomach Neoplasms - therapy</topic><topic>Studies</topic><topic>Survival analysis</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoney, A</creatorcontrib><creatorcontrib>Bati, Y</creatorcontrib><creatorcontrib>Isikli, L</creatorcontrib><creatorcontrib>Unsal, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Indian journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoney, A</au><au>Bati, Y</au><au>Isikli, L</au><au>Unsal, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative chemoradiation in patients with localized gastric adenocarcinoma: single center experience</atitle><jtitle>Indian journal of cancer</jtitle><addtitle>Indian J Cancer</addtitle><date>2011-01</date><risdate>2011</risdate><volume>48</volume><issue>1</issue><spage>24</spage><pages>24-</pages><issn>0019-509X</issn><eissn>1998-4774</eissn><abstract>5-Fluorouracil (FU)-based chemotherapy (CT) and concurrent 45 Gy radiotherapy (RT) is one of the standard postoperative approaches currently used in gastric carcinoma. The high toxicity rates of this treatment leads to interruption of treatment in the majority of patients. In our study, we investigated the rates of toxicity and treatment discontinuation observed during postoperative FU-based chemoradiotherapy (CRT); retrospectively evaluated the effect of CRT and the other prognostic factors on local and distant control and survival.
A total of 160 patients consisting of 97 total and 63 subtotal gastrectomy receiving postoperative CRT, have been studied retrospectively.
Patients who had to discontinue the treatment for a median of 6 (range, 3-13) days experienced toxicity during treatment at a rate of 43%. During the 21 (range, 4-68) months of follow-up local recurrences were observed in 8 (5%) patients and distant recurrences were observed in 41 (25.6%) patients. While the 1-3 year overall survival (OS) rates were 75% and 42%, 13-year disease-free survival (DFS) rates were 63% and 42%, respectively. In the univariate analysis for OS and DFS demonstrated statistical significance for below those 60 years of age, D1-D2 dissection type, negative surgical margin, early treatment beginning, the absence of invasion, and early stage disease. D1D2 dissection type, early treatment beginning, age below 60 years and early stage disease significantly improve OS and DFS in multivariate analysis.
Survival is worse in patients older than 60 years, had late treatment beginning, advanced stage and D0 dissection.</abstract><cop>India</cop><pub>Medknow Publications and Media Pvt. Ltd</pub><pmid>21248450</pmid><doi>10.4103/0019-509X.75816</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0019-509X |
ispartof | Indian journal of cancer, 2011-01, Vol.48 (1), p.24 |
issn | 0019-509X 1998-4774 |
language | eng |
recordid | cdi_proquest_journals_853032357 |
source | MEDLINE; Medknow Open Access Medical Journals; Bioline International; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Adenocarcinoma Adenocarcinoma - drug therapy Adenocarcinoma - radiotherapy Adenocarcinoma - therapy Adenocarcinoma, Mucinous - drug therapy Adenocarcinoma, Mucinous - radiotherapy Adenocarcinoma, Mucinous - therapy Adult Aged Antimetabolites, Antineoplastic - therapeutic use Cancer Carcinoma, Papillary - drug therapy Carcinoma, Papillary - radiotherapy Carcinoma, Papillary - therapy Carcinoma, Signet Ring Cell - drug therapy Carcinoma, Signet Ring Cell - radiotherapy Carcinoma, Signet Ring Cell - therapy Care and treatment Chemotherapy Combined Modality Therapy Dissection Female Fluorouracil - therapeutic use Follow-Up Studies Gastrectomy Humans Male Methods Middle Aged Mortality Patient outcomes Postoperative care Postoperative period Retrospective Studies Statistical methods Stomach Neoplasms - drug therapy Stomach Neoplasms - radiotherapy Stomach Neoplasms - therapy Studies Survival analysis Survival Rate Treatment Outcome |
title | Postoperative chemoradiation in patients with localized gastric adenocarcinoma: single center experience |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T19%3A30%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20chemoradiation%20in%20patients%20with%20localized%20gastric%20adenocarcinoma:%20single%20center%20experience&rft.jtitle=Indian%20journal%20of%20cancer&rft.au=Yoney,%20A&rft.date=2011-01&rft.volume=48&rft.issue=1&rft.spage=24&rft.pages=24-&rft.issn=0019-509X&rft.eissn=1998-4774&rft_id=info:doi/10.4103/0019-509X.75816&rft_dat=%3Cgale_proqu%3EA249582178%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=853032357&rft_id=info:pmid/21248450&rft_galeid=A249582178&rfr_iscdi=true |